Q2 2022 Earnings Estimate for Athenex, Inc. Issued By Oppenheimer (NASDAQ:ATNX)

Athenex, Inc. (NASDAQ:ATNXGet Rating) – Research analysts at Oppenheimer upped their Q2 2022 earnings estimates for shares of Athenex in a report issued on Tuesday, May 10th. Oppenheimer analyst K. Degeeter now anticipates that the company will post earnings per share of ($0.13) for the quarter, up from their prior forecast of ($0.14). Oppenheimer also issued estimates for Athenex’s Q3 2022 earnings at ($0.12) EPS, Q4 2022 earnings at ($0.12) EPS, FY2022 earnings at ($0.61) EPS and FY2023 earnings at ($0.44) EPS.

Several other research firms have also commented on ATNX. Zacks Investment Research lowered shares of Athenex from a “buy” rating to a “hold” rating in a research report on Friday, April 15th. SVB Leerink lifted their target price on shares of Athenex from $2.00 to $3.00 and gave the stock a “market perform” rating in a research note on Thursday, March 17th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $3.00.

NASDAQ:ATNX opened at $0.50 on Friday. The firm has a market capitalization of $55.91 million, a P/E ratio of -0.28 and a beta of 0.98. Athenex has a 1-year low of $0.43 and a 1-year high of $5.27. The company’s fifty day moving average price is $0.76 and its 200-day moving average price is $1.23. The company has a debt-to-equity ratio of 3.00, a current ratio of 1.39 and a quick ratio of 1.03.

Athenex (NASDAQ:ATNXGet Rating) last issued its earnings results on Tuesday, May 10th. The company reported ($0.16) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.03. Athenex had a negative net margin of 176.47% and a negative return on equity of 113.34%. During the same period in the prior year, the company posted ($0.27) EPS.

Hedge funds and other institutional investors have recently bought and sold shares of the business. HNP Capital LLC acquired a new position in Athenex during the 1st quarter worth approximately $27,000. Victory Capital Management Inc. acquired a new position in Athenex during the 3rd quarter worth approximately $34,000. BNP Paribas Arbitrage SA lifted its position in shares of Athenex by 432.5% during the 3rd quarter. BNP Paribas Arbitrage SA now owns 17,796 shares of the company’s stock worth $54,000 after buying an additional 14,454 shares during the last quarter. Marshall Wace LLP purchased a new stake in shares of Athenex during the 3rd quarter worth approximately $59,000. Finally, Cubist Systematic Strategies LLC lifted its position in shares of Athenex by 101.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 44,069 shares of the company’s stock worth $60,000 after buying an additional 22,141 shares during the last quarter. Institutional investors own 40.87% of the company’s stock.

About Athenex (Get Rating)

Athenex, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies.

Featured Articles

Earnings History and Estimates for Athenex (NASDAQ:ATNX)

Receive News & Ratings for Athenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athenex and related companies with MarketBeat.com's FREE daily email newsletter.